India has reduced prices across 1,031 anti-cancer medicine formulations, with the government estimating annual consumer savings of 3,502 crore rupees.
The Centre has approved a 30% trade-margin cap on non-scheduled cancer medicines, aiming to lower prices and reduce patients’ out-of-pocket treatment costs.